San Antonio Breast Cancer Symposium 2024
The 2024 San Antonio Breast Cancer Symposium (SABCS) meeting was held December 10-13, 2024 in San Antonio, TX and virtually. Click the links below to read about MBC research reported at this meeting.
Overview of New MBC Clinical Trial Data Presented at SABCS 2024
- Living Beyond Breast Cancer (webinar): In this webinar, Dr. Neil Vasan summarizes key clinical trial data from SABCS 2024, with an emphasis on the importance of minimizing side effects (Information for people with MBC is presented from the beginning to 37:30)
- Our MBC Life (podcast): This podcast features Dr. Debu Tripathy who breaks down into understandable terms some of the most impactful findings shared at SABCS
Triple-Positive MBC
- Breastcancer.org: Adding palbociclib (Ibrance®) to standard of care improves progression-free survival by 15 months in people with triple-positive MBC
Hormone Receptor Positive (HR+), HER2-Negative (HER2-) MBC
- Living Beyond Breast Cancer: Imlunestrant, an experimental oral SERD, worked better than standard of care when used alone in people with ESR1 mutations and when given with abemaciclib (Verzenio®) regardless of ESR1 mutation status in people with HR+, HER2- MBC
- Oncology News Central: Palbociclib (Ibrance®) plus hormone therapy is better than chemotherapy for HR+, HER2? MBC
- Breastcancer.org: Biomarkers and features of the cancer can help predict whether someone will respond to CDK4/6 inhibitors
HER2-Positive MBC
HER2-Low and HER2-Ultralow MBC
- Breastcancer.org (article and podcast): Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu®) works better than chemotherapy after disease progression while on hormone therapy for people with HR+, HER2-low or HER2-ultralow MBC